Advertisement

Topics

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

16:05 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Gene Therapy Leader Advancing Pipeline of Programs for Inherited Retinal Diseases, Including Upcoming Phase 3 Trial for Choroideremia NightstaRx Limited (“Nightstar”), a late-stage biopharmaceutical company developing ge...

Other Sources for this Article

THRUST IR
Alicia Davis, 910-620-3302
alicia@thrustir.com

NEXT ARTICLE

More From BioPortfolio on "Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...